Results 21 to 30 of about 8,510 (199)

Lorlatinib Achieved Rapid CNS Response in an 81-Year-Old NSCLC Patient With Performance Status Deterioration. [PDF]

Respirol Case Rep
Lorlatinib may offer rapid CNS symptom and imaging improvement after alectinib failure, even in elderly ALK‐positive NSCLC patients with declining performance status.
Nigi A, Iwamoto K, Itani H, Kondou S.
europepmc   +2 more sources

Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma. [PDF]

Pediatr Blood Cancer
The anaplastic lymphoma kinase (ALK) inhibitor lorlatinib demonstrated safety without pulmonary toxicity in early‐phase trials in patients with neuroblastoma. Lorlatinib is being tested with chemotherapy and immunotherapy in the Children's Oncology Group
Wei W, Fader ME, Kushner BH, Cardenas FI, Kramer K, Basu E, Modak S.   +6 more
europepmc   +2 more sources

Liver and Pancreatic Injury in Response to ALK Inhibitors in a Patient with Primary Signet Ring Cell Carcinoma of the Lung: A Case Report

Case Reports in Oncology, 2021
We report a patient with stage IV anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (primary lung signet ring cell adenocarcinoma) who received serial crizotinib, chemotherapy, and lorlatinib over more than 4 years.
Ibrahim Yildiz
doaj   +1 more source

A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier

Frontiers in Pharmacology, 2021
Of late, lorlatinib has played an increasingly pivotal role in the treatment of brain metastasis from non-small cell lung cancer. However, its pharmacokinetics in the brain and the mechanism of entry are still controversial. The purpose of this study was
Wei Chen, Chunyu Li, Yafei Shi, Yujun Zhang, Dujia Jin, Mingyu Zhang, Mingming Bo, Guohui Li   +7 more
doaj   +1 more source

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

JTO Clinical and Research Reports, 2023
Introduction: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan.
Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD   +22 more
doaj   +1 more source

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

npj Precision Oncology, 2022
Anaplastic lymphoma kinase (ALK) fusion is found in ~3%–5% of patients with non-small-cell lung cancers (NSCLCs). Although the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib shows high clinical efficacy in ALK-positive NSCLC, most of the
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama   +11 more
doaj   +1 more source

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. [PDF]

, 2020
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Al-Holou, Wajd, Armas, Octavio, Kubota, Takafumi, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Raval, Kunil, Robinette, Natasha, Zhu, Viola W   +7 more
core   +1 more source

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

Current Oncology, 2023
Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase ...
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu   +13 more
doaj   +1 more source

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

New England Journal of Medicine, 2020
BACKGROUND Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC).
A. Shaw, T. Bauer, F. de Marinis, E. Felip, Y. Goto, Geoffrey Liu, J. Mazières, Dong-Wan Kim, T. Mok, A. Polli, H. Thurm, A. Calella, G. Peltz, B. Solomon   +13 more
semanticscholar   +1 more source

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

JTO Clinical and Research Reports, 2023
Introduction: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than ...
Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD   +21 more
doaj   +1 more source